Serum CD44 in Non-Hodgkin's Lymphoma

References

• Goodfellow P. N., Banting G., Wiles M. V., Tunnacliffe A., Parkar M., Solomon E., Dalchau R., Fabre J. W. The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11. Eur. J. Immunol. 1982; 12: 659–663
   PubMed Web of Science ®Google Scholar
• Screaton G. R., Bell M. V., Jackson D. G., Cornelis F. B., Gerth U., Bell J. I. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl. Acad. Sci. USA 1992; 89: 12160–12164
   PubMed Web of Science ®Google Scholar
• Jalkanen S., Jalkanen M., Bargatze R., Tammi M., Butcher E. C. Biochemical properties of glycopro‐teins involved in lymphocyte recognition of high endothelial venules in man. J. Immunol. 1988; 141: 1615–1623
   PubMed Web of Science ®Google Scholar
• Brown T. A., Bouchard T., St. John T., Wayner E., Carter W. G. Human keratinocytes express a new CD44 core protein (CD44E) as a heparan‐sulfate intrinsic membrane proteoglycan with additional exons. J. Cell Biol. 1991; 113: 207–221
   PubMed Web of Science ®Google Scholar
• Jackson D. G., Bell J. I., Dickinson R., Timans J., Shields J., Whittle N. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J. Cell Bid. 1995; 128: 673–685
   PubMed Web of Science ®Google Scholar
• Zhou D. F., Ding J. F., Picker L. J., Bargatze R. F., Butcher E. C., Goeddel D. V. Molecular cloning and expression of Pgp‐1. The mouse homolog of the human H‐CAM (Hermes) lymphocyte homing receptor. J. Iinmunol. 1989; 143: 3390–3395
   PubMed Web of Science ®Google Scholar
• Jalkanen S. T., Bargatze R. F., Herron L. R., Butcher E. C. A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man. Eur. J. Immunol. 1986; 16: 1195–1202
   PubMed Web of Science ®Google Scholar
• Picker L. J., Nakache M., Butcher E. C. Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J. Cell Biol. 1989; 109: 927–937
   PubMed Web of Science ®Google Scholar
• Shimizu Y., Van Seventer G. A., Siraganian R., Wahl L., Shaw S. Dual role of the CD44 molecule in T cell adhesion and activation. J. Immunol. 1989; 143: 2457–2463
   PubMed Web of Science ®Google Scholar
• Haynes B. E., Telen M. J., Hale L. P., Denning S. M. CD44–a molecule involved in leukocyte adherence and T‐cell activation [published erratum appears in Immunol Today 1990 Mar; 11(3):80. Immunol. Today 1989; 10: 423–428
   PubMedGoogle Scholar
• Miyake K., Medina K. L., Hayashi S., Ono S., Hamaoka T., Kincade P. W. Monoclonal antibodies to Pgp‐1/CD44 block lympho‐hemopoiesis in long‐term bone marrow cultures. J. Exp. Med. 1990; 171: 477–488
   PubMed Web of Science ®Google Scholar
• Koopman G., van Kooyk Y., de Graaff M., Meyer C. J., Figdor C. G., Pals S. T. Triggering of the CD44 antigen on T lymphocytes promotes T cell adhesion through the LFA‐I pathway. J. Immunol. 1990; 145: 3589–3593
   PubMed Web of Science ®Google Scholar
• Bennett K. L., Jackson D. G., Simon J. C., Tanczos E., Peach R., Modrell B., Stamenkovic I., Plowman G., Aruffo A. CD44 isoforms containing exon V3 are responsible for the presentation of heparin‐binding growth factor. J. Cell Biol. 1995; 128: 687–698
   PubMed Web of Science ®Google Scholar
• Yu Q., Took B. P., Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J. Exp. Med. 1997; 186: 1985–1996
   PubMedGoogle Scholar
• Aruffo A., Stamenkovic I., Melnick M., Underhill C. B., Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 1303–1313
   PubMed Web of Science ®Google Scholar
• Underhill C. CD44: the hyaluronan receptor. J. Cell Sci. 1992; 103: 293–298
   PubMed Web of Science ®Google Scholar
• Stamenkovic I., Aruffo A., Amiot M., Seed B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate‐ bearing cells. EMBO J. 1991; 10: 343–348
   PubMed Web of Science ®Google Scholar
• Perschl A., Lesley J., English N., Trowbridge I., Hyman R. Role of CD44 cytoplasmic domain in hyaluronan binding. Eur: J. Immunol. 1995; 25: 495–501
   PubMed Web of Science ®Google Scholar
• Lesley J., English N., Perschl A., Gregoroff J., Hyman R. Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation. J. Exp. Med. 1995; 182: 431–437
   PubMed Web of Science ®Google Scholar
• Katoh S., Zheng Z., Oritani K., Shimozato T., Kincade P. W. Glycosylation of CD44 negatively regulates its recognition of hyaluronan. J. Exp. Med. 1995; 182: 419–429
   PubMed Web of Science ®Google Scholar
• Jalkanen S., Jalkanen M. Lymphocyte CD44 binds the COOH‐terminal heparin‐binding domain of fibronectin. J. Cell Biol. 1992; 116: 817–825
   PubMed Web of Science ®Google Scholar
• Wayner E. A., Carter W. G. ldentification of multiple cell adhesion receptors for collagen and fibronectin in human fibrosarcoma cells possessing unique alpha and common beta subunits. J. Cell Biol. 1987; 105: 1873–1884
   PubMed Web of Science ®Google Scholar
• Carter W. G., Wayner E. A. Characterization of the class III collagen receptor, a phosphorylated, transmem‐brane glycoprotein expressed in nucleated human cells. J. Biol. Chem. 1988; 263: 4193–4201
   PubMed Web of Science ®Google Scholar
• Toyama Sorimachi N., Sorimachi H., Tohita Y., Kitamura F., Yagita H., Suzuki K., Miyasaka M. A novel ligand for CD44 is serglycin, a hematopoietic cell lineage‐specific proteoglycan. Possible involvement in lymphoid cell adherence and activation. J. Biol. Chem. 1995; 270: 7437–7444
   PubMed Web of Science ®Google Scholar
• Weber G. F., Ashkar S., Glimcher M. J., Cantor H. Receptor‐ligand interaction between CD44 and osteopontin (Eta‐1). Science 1996; 271: 509–512
   PubMed Web of Science ®Google Scholar
• Naujokas M. F., Morin M., Anderson M. S., Peterson M., Miller J. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 1993; 74: 257–268
   PubMed Web of Science ®Google Scholar
• Horst E., Meijer C. J., Radaszkiewicz T., Ossekoppele G. J., Van Krieken J. H., Pals S. T. Adhesion molecules in the prognosis of diffuse large‐cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA‐ I (CD11a/18), and ICAM‐I (CD54). Leukemia 1990; 4: 595–599
   PubMed Web of Science ®Google Scholar
• Jalkanen S., Joensuu H., Soderstrom K. O., Klemi P. Lymphocyte homing and clinical behavior of non‐Hodgkin's lymphoma. J. Clin. Invest. 1991; 87: 1835–1840
   PubMed Web of Science ®Google Scholar
• Guo Y., Ma J., Wang J., Che X., Narula J., Bigby M., Wu M., Sy M. S. Inhibition of human melanoma growth and metastasis in vivo by anti‐CD44 monoclonal antibody [published erratum appears in Cancer Res 1994 Apr 15; 54(8):2284]. Cancer Res. 1994; 54: 1561–1565
   PubMed Web of Science ®Google Scholar
• Sy M. S., Guo Y. J., Stamenkovic I. Inhibition oftumor growth in vivo with a soluble CD44– immunoglobu‐lin fusion protein. J. Exp. Med. 1992; 176: 623–627
   PubMed Web of Science ®Google Scholar
• Gunthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussmann I., Matzku S., Wenzel A., Ponta H., Her‐rlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13–24
   PubMed Web of Science ®Google Scholar
• Dalchau R., Kirkley J., Fabre J. W. Monoclonal antibody to a human brain‐granulocyte‐T lymphocyte antigen probably homologous to the W 3/13 antigen of the rat. Eur. J. Immunol. 1980; 10: 745–749
   PubMed Web of Science ®Google Scholar
• Telen M. J., Eisenbarth G. S., Haynes B. F. Human erythrocyte antigens. Regulation of expression of a novel erythrocyte surface antigen by the inhibitor Lutheran In(Lu) gene. J. Clin. Invesr. 1983; 71: 1878–1886
   PubMed Web of Science ®Google Scholar
• Lucas M. G., Green A. M., Telen M. J. Characterization ofthe serum In(Lu)‐related antigen: identification of a serum protein related to erythrocyte p80. Blood 1989; 73: 596–600
   PubMed Web of Science ®Google Scholar
• Haynes B. F., Hale L. P., Patton K. L., Martin M. E., McCallum R. M. Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up‐reg‐ulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis. Rheum. 1991; 34: 1434–1443
   PubMed Web of Science ®Google Scholar
• Katoh S., McCarthy J. B., Kincade P. W. Characterization of soluble CD44 in the circulation of mice. Levels are affected by immune activity and tumor growth. J. Immunol. 1994; 153: 3440–3449
   PubMed Web of Science ®Google Scholar
• Bazil V., Horejsi V. Shedding ofthe CD44 adhesion molecule from leukocytes induced by anti‐CD44 monoclonal antibody simulating the effect of a natural receptor ligand. J. Immunol. 1992; 149: 747–753
   PubMed Web of Science ®Google Scholar
• Camp R. L., Scheynius A., Johansson C., Pure E. CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation. J. Exp. Med. 1993; 178: 497–507
   PubMed Web of Science ®Google Scholar
• Campanero M. R., Pulido R., Alonso J. L., Pivel J. P., Muinos Pimentel F.X., Fresno M., Sanchez Madrid F. Down‐regulation by tumor necrosis factor‐alpha of neutrophil cell surface expression of the sialophorin CD43 and the hyaluronate receptor CD44 through a proteolytic mechanism. Eur: J. Immunol. 1991; 21: 3045–3048
   PubMed Web of Science ®Google Scholar
• Bazil V., Strominger J. L. Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. Induction of cleavage of L‐selectin via CD16. J. Immunol. 1994; 152: 1314–1322
   PubMed Web of Science ®Google Scholar
• Guo Y. J., Liu G., Wang X., Jin D., Wu M., Ma J., Sy M. S. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res. 1994; 54: 422–426
   PubMed Web of Science ®Google Scholar
• Martin S., Jansen F., Bokelmann J., Kolb H. Soluble CD44 splice variants in metastasizing human breast cancer. Int. J. Cancel. 1997; 74: 443–445
   PubMed Web of Science ®Google Scholar
• Kittl E. M., Ruckser R., Selleny S., Samek V., Hofmann J., Huber K., Reiner A., Ogris E., Hinterberger W., Bauer K. Evaluation of soluble CD44 splice variant v5 in the diagnosis and follow‐up in breast cancer patients. Exp. Clin. Immunogenet. 1997; 14: 264–272
   PubMedGoogle Scholar
• Gadducci A., Ferdeghini M., Fanucchi A., Annicchiarico C., Cosio S., Prontera C., Bianchi R., Genazzani A. R. Serum assay of soluble CD44 standard (sCD44‐st), CD44 splice variant vS (sCD44‐vS), and CD44 splice variant v6 (sCD44‐v6) in patients with epithelial ovarian cancer. Anticancer Res. 1997; 17: 4463–4466
   PubMed Web of Science ®Google Scholar
• Zeimet A. G., Widschwendter M., Uhl Steidl M., Holzner Muller E., Daxenbichler G., Marth C., Dapunt O. High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer. Br. J. Cancer 1997; 76: 1646–1651
   PubMed Web of Science ®Google Scholar
• Dc Rossi G., Marroni P., Paganuzzi M., Mauro F. R., Tenca C., Zarcone D., Velardi A., Molica S., Grossi C. E. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lym‐phocytic leukemia. Leukemia 1997; 11: 134–141
   Web of Science ®Google Scholar
• Ristamäki R., Joensuu H., Grön‐Virta K., Salmi M., Jalkanen S. Origin and function of circulating CD44 in non‐Hodkgin's lymphoma. J. Immunol. 1997; 158: 3000–3008
   PubMed Web of Science ®Google Scholar
• Clayberger C., Wright A., Medeiros L. J., Koller T. D., Link M. P., Smith S. D., Warnke R. A., Krensky A. M. Absence of cell surface LFA‐1 as a mechanism of escape from immunosurveillance. Lancet 1987; 2: 533–536
   PubMed Web of Science ®Google Scholar
• Ristamäki R., Joensuu H., Salmi M., Jalkanen S. Serum CD44 in malignant lymphoma: an association with treatment response. Blood 1994; 84: 238–243
   PubMed Web of Science ®Google Scholar
• Ristamäki R., Joensuu H., Hagberg H., Kälkner K. M., S. J. Clinical significance of circulating CD44 in non‐Hodgkin's lymphoma. Int. J. Cancei 1998; 79: 221–225
   PubMed Web of Science ®Google Scholar
• Ristamaki R., Joensuu H., Lappalainen K., Teerenhovi L., Jalkanen S. Elevated serum CD44 level is associated with unfavorable outcome in non‐Hodgkin's lymphoma. Blood 1997; 90: 4039–4045
   PubMed Web of Science ®Google Scholar
• Kittl E. M., Ruckser R., Rech‐Weichselbraun I., Hinterberger W., Bauer K. Significant elevation of tumour‐associated isoforms of soluble CD44 in serum of normal individuals caused by cigarette smoking. Eur. J. Clin. Chem. Clin. Biochem. 1997; 35: 81–84
   PubMedGoogle Scholar
• Guo Y. J., Liu G., Wang X., Jin D., Wu M., Ma J., Sy M. S. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res. 1994; 54: 422–426
   PubMed Web of Science ®Google Scholar